期刊
BREAST CANCER RESEARCH
卷 2, 期 3, 页码 176-183出版社
BMC
DOI: 10.1186/bcr51
关键词
epidermal growth factor receptor; ErbB-2; ErbB-3; ErbB4; HER2/neu
类别
资金
- NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA45708, R01 CA045708] Funding Source: Medline
ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据